Mezigdomide

1 article

A futuristic laboratory setting with a holographic display showcasing positive patient survival data for a new cancer treatment.

Bristol Myers Squibb shows strong multiple myeloma data

In a significant development for multiple myeloma patients, Bristol Myers Squibb's mezigdomide triplet demonstrated a median progression-free survival of 18 months, more than doubling the 8.

David Grossman·May 30, 2026